Stock Detail
THERAVANCE INC
Biotechnology
THRX @ Yahoo Finance | THRX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $23.14 | $23.85 | $-0.26 | -1.11% | 0.00 | $23.40 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $23.00 | $22.89 | 391,168 | 1.97B | 383,859.5 | -19.12 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 24.25 | 23.69 | 23.29 | 22.73 | 22.33 |
Stock Profile
Theravance, Inc. engages in the discovery, development, and commercialization of small molecule medicines for respiratory disease, bacterial infections, overactive bladder, and gastrointestinal disorders. As of April 7, 2005, telavancin, the company's injectable antibiotic, was in Phase 3 clinical studies for the treatment of Gram-positive infections and in patients whose infections were due to methicillin-resistant Staphylococcus aureus in both complicated skin and skin structure infections and hospital-acquired pneumonia. Its other product candidates in development include TD-6301 for overactive bladder; TD-2749 and TD-5108 for gastrointestinal motility dysfunction; and TD-4756 for emergence from hypnosis. Theravance has various other product candidates in the identification and preclinical testing stages. The company has a collaboration agreement with GlaxoSmithKline (GSK) to develop and commercialize long acting beta2 agonist product candidates for the treatment of asthma and chronic obstructive pulmonary disease. It also has a strategic alliance with GSK. Theravance, Inc. has collaboration with Astellas Pharma, Inc. for the development and commercialization of its investigational antibiotic, telavancin. The company was co-founded by P. Roy Vagelos and George M. Whitesides in 1996. It was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in 2002. Theravance is headquartered in South San Francisco, California.